Argent BioPharma Limited
RGT.L · LSE
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | -0.01 | 0.01 |
| FCF Yield | -103.52% | -1,064.24% | -1,540.39% | -1,791.43% |
| EV / EBITDA | -0.90 | -0.07 | -0.17 | -0.10 |
| Quality | ||||
| ROIC | 1,433.59% | 494.00% | -107.81% | -53.91% |
| Gross Margin | 22.86% | 42.83% | 38.25% | 44.21% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -42.68% | 4.57% | 59.87% | 101.38% |
| Free Cash Flow Growth | -18.20% | 17.96% | 3.04% | -151.86% |
| Safety | ||||
| Net Debt / EBITDA | -0.02 | -0.02 | -0.12 | -0.04 |
| Interest Coverage | -34.61 | -60.60 | -67.86 | -32.70 |
| Efficiency | ||||
| Inventory Turnover | 0.79 | 1.42 | 1.59 | 1.89 |
| Cash Conversion Cycle | 151.82 | -97.87 | 63.75 | 212.05 |